endometrial hyperplasia

News

Bayer has started a phase 3 trial of its Mirena contraceptive in an endometrial disorder, with no treatments, that can lead to cancer.

News

CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.